Product overview
Thymosin Alpha-1 10mg/10vials is a sterile lyophilized research peptide. Thymosin Alpha-1 (Tα1) is a 28-amino-acid acetylated peptide originally isolated from thymus tissue in the 1970s by Allan Goldstein and colleagues, and characterized as one of the active fractions of the older thymic-extract preparation thymosin fraction 5. It has a substantial preclinical literature on innate-immunity and adaptive-immunity endpoints, particularly in models of viral exposure and immunosenescence.
Independently assayed by HPLC and MS, and lot-traceable to the source preparation.
Typical research dose range
Published preclinical and early clinical immunology protocols use Thymosin Alpha-1 in the range of roughly 1.6 mg per administration twice weekly in human-equivalent dosing schedules, with proportional scaling in animal models. Researchers should consult source literature for the specific endpoint, model organism, and exposure pattern.
Stack and pairing
Thymosin Alpha-1 is studied alongside Thymosin Beta-4 (TB-500) in protocols that examine both adaptive-immune (Tα1) and connective-tissue (TB-4) endpoints. It is also included in study designs that examine immunosenescence in aged animal models, where it is sometimes paired with Epithalon for combined endpoint coverage.
Reconstitution and storage
Reconstitute each vial with 1-2 mL of bacteriostatic water for the target working concentration. Use sterile technique. Once reconstituted, store at 2-8 °C and use within 30 days for best stability.
Lyophilized vials should be kept refrigerated at 2-8 °C until first use. For long-term storage beyond six months, store at -20 °C in the original sealed vial. Avoid repeated freeze-thaw cycles.
Kit contents
- 10 × 10mg vials of lyophilized Thymosin Alpha-1
- 1 × certificate of analysis (lot-specific)
- 1 × handling and reconstitution insert
